Concordance for myositis-specific autoantibody detection between commercial ELISA and line blot assays: a multicentre study conducted across the Asia-Pacific region
Authors' conclusion
Discrepancies in the measurement results were observed between commercially available ELISA and LBA, especially for anti-PL7 and anti-Mi-2. ELISA is more accurate than LBA.
Study context
- Population
- Patients with IIM from seven countries across the Asia-Pacific region
- Participants
- 485 patients7 countries
- Comparison
- Commercial ELISA vs line blot assay for myositis-specific autoantibodies
- Outcome
- Concordance (PPA, NPA, Cohen's kappa) between ELISA and LBA for anti-Jo-1, anti-EJ, anti-PL-7, anti-PL-12, anti-MDA5, anti-Mi-2 and anti-TIF1-γ
Methodological detailsmulticentre, central measurement, immunoprecipitation of discordant sera
- Multicentre
- Central measurement
- Immunoprecipitation of discordant sera
Performance
As reported in the abstract
Positive percentage agreement (PPA), ELISA vs LBA
- Positive percentage agreement (PPA) anti-Jo-1
- 0.98
- PPA anti-PL-7
- 0.94
- PPA anti-EJ
- 0.93
- PPA anti-MDA5
- 0.93
- PPA anti-TIF1-γ
- 0.89
- PPA anti-PL-12
- 0.78
- PPA anti-Mi-2
- 0.67
- Negative percentage agreement (NPA), all myositis-specific autoantibodies (MSAs) (range)
- 0.97 to 1
Further findings
Immunoprecipitation (IP) of discordant sera
- High rate of false positives for anti-PL-7 and anti-Mi-2 in line blot assays (LBA)
Original publication
Concordance for myositis-specific autoantibody detection between commercial ELISA and line blot assays: a multicentre study conducted across the Asia-Pacific region. Rheumatology (Oxford). Published 16 June 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →